cyanato-3-fluorobenzene | 25245-14-1

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: cyanato-3-fluorobenzene
• 英文别名: (3-Fluorophenyl) cyanate
• CAS: 25245-14-1
• 化学式: C₇H₄FNO
• 分子量: 137.113
• InChiKey: GHGXXELCRARJOI-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2
• 重原子数：
  10
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  33
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  cyanato-3-fluorobenzene 在 O-(四氢-2H-吡喃-2-基)羟基胺 作用下， 以 四氢呋喃 为溶剂， 生成
  参考文献：
  名称：

  WO2006/129199

  摘要：

  公开号：

文献信息

• USE OF PYRIDINE UREA COMPOUND HAVING SNAIL-KILLING ACTIVITY
  申请人：THE NATIONAL INSTITUTE OF PARASITIC DISEASES, CHINESE CENTER FOR DISEASE CONTROL AND PREVENTION

  公开号：US20210022340A1

  公开（公告）日：2021-01-28

  The present invention relates to use of a pyridine urea compound having snail-killing activities, and relates to a method for preparing the pyridine urea compound. In particular, the present invention discloses a compound having the structure as shown in formula (I), an optical isomer thereof, a racemate thereof, a solvate thereof, or a pharmaceutically acceptable salt thereof, the compound having a significant killing effect on various snails as parasitic disease vectors and low toxicity to non-target organism fish.

  本发明涉及使用具有杀螺活性的吡啶脲化合物，并涉及制备该吡啶脲化合物的方法。具体而言，本发明揭示了具有如化学式（I）所示结构的化合物，其光学异构体、外消旋体、溶剂合物或药用可接受盐，该化合物对各种蜗牛作为寄生疾病传播媒介具有显著的杀灭效果，并对非靶标生物鱼类具有低毒性。
• CHROMAN DERIVATIVES AS TRPM8 INHIBITORS
  申请人：AMGEN INC.

  公开号：US20140045855A1

  公开（公告）日：2014-02-13

  Chroman compounds and derivatives of Formula I are useful inhibitors of TRPM8. Such compounds are useful in treating a number of TRPM8 mediated disorders and conditions and may be used to prepare medicaments and pharmaceutical compositions useful for treating such disorders and conditions. Examples of such disorders include, but are not limited to, migraines and neuropathic pain. Compounds of Formula I have the following structure: where the definitions of the variables are provided herein.

  Formula I的Chroman化合物和衍生物是TRPM8的有用抑制剂。这些化合物在治疗多种由TRPM8介导的疾病和症状方面具有用途，并可用于制备治疗这些疾病和症状的药物和药物组合物。这些疾病的例子包括，但不限于，偏头痛和神经病性疼痛。Formula I的化合物具有以下结构：变量的定义在此提供。
• Novel Heterocyclic Compounds as Positive Allosteric Modulators of Metabotropic Glutamate Receptors
  申请人：Farina Marco

  公开号：US20100004284A1

  公开（公告）日：2010-01-07

  The present invention relates to new compounds which are Heterocyclic derivatives of formula (I) wherein A, B, P, X, Y, Q, W, R 1 and R 2 are defined in the description. Invention compounds are useful for treating central or peripheral nervous system disorders and other disorders which are affected by the neuromodulatory effect of mGluR5 positive allosteric modulators such as cognitive decline and also to treat both positive and negative symptoms in schizophrenia.

  本发明涉及公式（I）的新化合物，其为杂环衍生物，其中A，B，P，X，Y，Q，W，R1和R2在说明书中定义。发明化合物可用于治疗中枢或外周神经系统疾病以及其他受mGluR5阳性变构调节剂神经调节作用影响的疾病，如认知衰退，并可用于治疗精神分裂症的阳性和阴性症状。
• COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM
  申请人：VELICELEBI GONUL

  公开号：US20110212970A1

  公开（公告）日：2011-09-01

  Described herein are compounds and pharmaceutical compositions containing such compounds, which modulate the activity of store-operated calcium (SOC) channels. Also described herein are methods of using such SOC channel modulators, alone and in combination with other compounds, for treating diseases or conditions that would benefit from inhibition of SOC channel activity.

  本文介绍了一些化合物和含有这些化合物的药物组合物，它们可以调节储存操作钙（SOC）通道的活性。本文还介绍了使用这些SOC通道调节剂的方法，单独或与其他化合物结合，用于治疗需要抑制SOC通道活性的疾病或情况。
• CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS
  申请人：NEUPHARMA, INC.

  公开号：US20150158826A1

  公开（公告）日：2015-06-11

  Chemical entities based on quinoxaline that are kinase inhibitors are described. Specifically quinoxaline derivatives of Formula I, containing a diarylamide or diarylurea substructure that inhibit Braf mutant kinase activity, pharmaceutical compositions containing the inhibitor compounds and methods of treatment of cancer comprising administering an effective amount of the Braf inhibitor compound are described.

  描述了基于喹啉的化合物，它们是激酶抑制剂。具体地，描述了公式I的喹啉衍生物，包含二芳基酰胺或二芳基脲亚结构，可抑制Braf突变激酶活性，以及含有该抑制剂化合物的制药组合物和治疗癌症的方法，包括给予有效量的Braf抑制剂化合物。